| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product revenue, net | 83,127 | 85,807 | 74,380 | 71,539 |
| Cost of goods sold | 10,574 | 10,947 | 10,996 | 11,898 |
| Research and development | 8,783 | 7,874 | 7,483 | 8,055 |
| Selling, general and administrative | 53,144 | 47,502 | 46,459 | 44,393 |
| Amortization of intangible assets | 2,710 | 2,711 | 2,711 | 2,711 |
| Total costs and expenses | 75,211 | 69,034 | 67,649 | 67,057 |
| Income (loss) from operations | 7,916 | 16,773 | 6,731 | 4,482 |
| Loss on debt extinguishment, net | NaN | 0* | NaN | NaN |
| Debt refinancing costs | NaN | 0* | 0 | 0 |
| Interest and other income | 1,202 | 1,461 | 1,158 | 948 |
| Interest expense | 6,884 | 7,153 | 7,268 | 7,358 |
| Change in fair value of warrants | NaN | 0* | 0 | 0 |
| Change in fair value of contingent value rights | NaN | 0* | 0 | 0 |
| Total other expense | -5,682 | -5,692 | -6,110 | -6,410 |
| Net income (loss) before income taxes | 2,234 | 11,081 | 621 | -1,928 |
| U.s. federal statutory tax rate | NaN | -29* | NaN | NaN |
| State and local income taxes, net of federal income tax effect | NaN | 0* | NaN | NaN |
| Statutory tax rate difference between ireland and united states-IE | NaN | 958* | NaN | NaN |
| Changes in valuation allowance-IE | NaN | 1,515* | NaN | NaN |
| Other | NaN | 12* | NaN | NaN |
| Statutory tax rate difference between ireland and united states-Foreign Tax Jurisdiction Other | NaN | 73* | NaN | NaN |
| Subpart f income | NaN | -3,151* | NaN | NaN |
| Research and development tax credits | NaN | -306* | NaN | NaN |
| Changes in valuation allowance-US | NaN | 928* | NaN | NaN |
| Compensation subject to the section 162 limitation | NaN | -319* | NaN | NaN |
| Stock compensation | NaN | -199* | NaN | NaN |
| Non-deductible expenses | NaN | -69* | NaN | NaN |
| Other adjustments | NaN | -24* | NaN | NaN |
| Income tax benefit | 0 | 0 | 0 | 0 |
| Net income (loss) | 2,234 | 11,081 | 621 | -1,928 |
| Unrealized gains (losses) on investments | NaN | 0 | 0 | 0 |
| Other comprehensive income (loss), foreign currency transaction and translation gain (loss) arising during period, net of tax | 1 | NaN | -1 | 1 |
| Comprehensive income (loss) | 2,235 | 11,081 | 620 | -1,927 |
| Basic EPS | 0.01 | 0.067 | 0 | -0.01 |
| Diluted EPS | 0.01 | 0.055 | 0 | -0.01 |
| Basic Average Shares | 170,523,208 | 166,145,512 | 163,649,932 | 159,459,413 |
| Diluted Average Shares | 177,631,154 | 201,448,225 | 177,617,307 | 159,459,413 |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)